Synopsys (SNPS) is a buy: discounted valuation, pricing power, secular EDA growth, and Elliott catalyst. Read more macro analysis here.
Mr. Wu and Mr. Huang, who will share more about our e-commerce and brand management segment, respectively. Before we begin, I ...
Good afternoon, investors, and welcome to the AAC Technologies 2025 Annual Results Announcement Investor Conference. I'm the host of this event, Joyce Huang, IR Director at AAC Technologies. First, on ...
The following is an excerpt from Chairman and CEO David Solomon’s letter to shareholders, which was published in Goldman ...
The FDA's March 7, 2026 final rule mandating a uniform 12-digit National Drug Code—effective March 7, 2033, with a three-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results